Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Up - Still a Buy?

Key Points

• Zealand Pharma A/S shares gapped up significantly, opening at $76.79 after a previous close of $70.89, with 333 shares traded.
• Multiple analysts have upgraded the stock to a "strong-buy" rating, with an average rating of "Strong Buy" among seven research firms.
• The company reported $16.06 earnings per share (EPS) for the last quarter, missing estimates, with anticipated earnings of -2.19 EPS for the current year.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) gapped up prior to trading on Wednesday . The stock had previously closed at $70.89, but opened at $76.79. Zealand Pharma A/S shares last traded at $76.79, with a volume of 333 shares changing hands.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Barclays raised Zealand Pharma A/S to a "strong-buy" rating in a report on Monday, July 7th. Wells Fargo & Company raised Zealand Pharma A/S to a "strong-buy" rating in a report on Thursday, July 24th. Zacks Research raised Zealand Pharma A/S from a "strong sell" rating to a "hold" rating in a report on Monday, September 15th. Finally, BNP Paribas raised Zealand Pharma A/S to a "strong-buy" rating in a report on Tuesday, July 1st. Five equities research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Strong Buy".

Zealand Pharma A/S Trading Up 8.3%

The company has a market capitalization of $5.45 billion, a price-to-earnings ratio of 5.39 and a beta of 0.73. The company has a debt-to-equity ratio of 0.02, a quick ratio of 15.08 and a current ratio of 15.09. The firm has a fifty day moving average price of $63.38 and a 200-day moving average price of $64.82.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last released its earnings results on Thursday, August 14th. The company reported $16.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $16.72 by ($0.66). The company had revenue of $1.43 billion for the quarter, compared to analyst estimates of $9.18 billion. Zealand Pharma A/S had a return on equity of 67.06% and a net margin of 73.90%. As a group, equities analysts anticipate that Zealand Pharma A/S will post -2.19 EPS for the current year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.